Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE)

Journal of Medicinal Chemistry

Volumn 44, Issue 24, 2001, Pages 4252-4267

  Rabinowitz, M H ^a   Andrews, R C ^a,b   Becherer, J D ^a   Bickett, D M ^a   Bubacz, D G ^a   Conway, J G ^a   Cowan, D J ^a   Gaul, M ^a,d   Glennon, K ^a   Lambert, M H ^a   Leesnitzer, M A ^a   McDougald, D L ^a   Moss, M L ^a,c   Musso, D L ^a   Rizzolio, M C ^a  

^a GLAXOSMITHKLINE   (United States)

^b TransTech Pharma Inc   (United States)

^c Optimal Screening Vehicles Division   (United States)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMALYSIN; GELATINASE B; GW 3333; INTERSTITIAL COLLAGENASE; N [4 NITROGUANYL 1 [(1,3 THIAZOL 2 YLAMINO)CARBONYL]BUTYL] 3 [FORMYL(HYDROXY)AMINO] 2 ISOBUTYLHEXANAMIDE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG DESIGN; DRUG SOLUBILITY; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MOLECULAR MODEL; NONHUMAN; PHYSICAL CHEMISTRY; PLEURISY; RAT; X RAY DIFFRACTION;

ADAM PROTEINS; ANIMALS; ARGININE; CATALYTIC DOMAIN; CELL LINE; EXUDATES AND TRANSUDATES; FEMALE; FORMAMIDES; GUANIDINES; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MALE; METALLOENDOPEPTIDASES; MICE; MODELS, MOLECULAR; MOLECULAR MIMICRY; PLEURISY; PROTEASE INHIBITORS; RATS; RATS, INBRED LEW; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035935706     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0102654     Document Type: Article

References (53)

1. The pathophysiology of tumor necrosis factors
2. Tumor necrosis factor-α: Molecular-biological aspects. Minireview
3. Tumor necrosis factor-dependent production of human immunodeficiency virus 1 in chronically infected HL-60 cells
4. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (Ca2) versus placebo in rheumatoid arthritis
5. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome
6. Tumor necrosis factor α: A key component of the obesity-diabetes link
7. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease
8. The tumor necrosis factor-α converting enzyme
9. TACE and other ADAM proteases as targets for drug discovery
10. Crystal structure of the soluble human 55 Kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation
11. Two tumor necrosis factor receptors: Structure and function
12. Mice deficient for the 55 Kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
13. Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I
14. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-KB, degradation of IKBα nuclear translocation of P65, and subsequent gene expression
15. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-κB expression and lymphocyte function
16. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells
17. Infliximab: A review of its use in Crohn's disease and rheumatoid arthritis
18. Recombinant human tumor necrosis factor receptor (P75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis
19. Tumour necrosis factor-alpha blockade: A new era for effective management of rheumatoid arthritis
20. Safety of infliximab in clinical trials
21. Reactions to biological therapeutic agents
22. Design and development of small-molecule inhibitor of tumor necrosis factor-α
23. Processing of tumour necrosis factor-α precursor by metalloproteinases
24. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
25. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor
26. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells
27. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α
28. ADAMS: Focus on the protease domain
29. Intracellular maturation and localization of the tumour necrosis factor α convertase (TACE)
30. Preparation of arylsulfonylheterocyclylhydroxamic acids as metalloproteinase and TNF inhibitors for the treatment of inflammatory disorders
31. Selective matrix metalloproteinase (MMP) inhibitors having reduced side-effects
32. TACE: A disintegrin metalloprotease that regulates TNF-α production in vitro and in vivo
33. Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α converting enzyme and matrix metalloproteinases
34. Refined 2.0 Å x-ray crystal structure of the snake venom zinc endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin
35. Docking conformationally flexible molecules into protein binding sites
36. 1 values for heterocycles
37. Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme
38. High throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)
39. A high throughput assay for the TNF converting enzyme
40. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes
41. Asymmetric hydrogenation of β-Keto carboxylic esters. A practical, purely chemical access to β-hydroxy esters in high enantiomeric purity
42. Diastereoselective α-alkylation of β-hydroxycarboxylic esters through alkoxide enolates: (+)-Diethyl (2S, 3R) 3-Allyl-2-Hydroxysuccinate from (-)-diethyl S-Malate (butanedioic acid, 2-hydroxy-3-(2-propenyl)-diethyl ester, [S-(R, S)])
43. Acetic formic anhydride
44. Design and reactivity of organic functional groups - 2-Pyridylsulfonates as nucleofugal esters: Remarkably mild transformations into halides and olefins
45. Synthesis of chiral γ,δ-unsaturated amino acids by asymmetric ester enolate claisen rearrangement
46. The asymmetric ester enolate claisen rearrangement as a suitable method for the synthesis of sterically highly demanding amino acids
47. Conformational Analysis. IX. Gem-dimethyl effect
48. G-nitro-L-arginine methyl ester in patients with septic shock
49. N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents